Ranibizumab
Antineovascularisation Agents
Sold as Vislyfa · Byooviz · Ximluci · Susvimo · Lucentis
- Drug class
- Antineovascularisation Agents
- Availability
- See label
- Routes
- Intravitreal
- Markets covered
- 3
- Products on record
- 26
Overview
Ranibizumab is an active pharmaceutical ingredient in the Antineovascularisation Agents group (S01LA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 14 | May 29, 2026 |
| EU European Union | EMA | 7 | May 29, 2026 |
| CA Canada | Health Canada | 5 | December 24, 2025 |
GBUnited Kingdom· MHRA
14 products
Uses
Lucentis is indicated in adults for: • The treatment of neovascular (wet) age-related macular degeneration (AMD) • The treatment of visual impairment due to diabetic macular oedema (DME) • The treatment of proliferative diabetic retinopathy (PDR) • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • The treatment of visual impairment due to choroidal neovascularisation (CNV) Lucentis is indicated in preterm infants for: • The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
How to take
EUEuropean Union· EMA
7 products
Uses
Ranluspec is indicated in adults for: • The treatment of neovascular (wet) age-related macular degeneration (AMD) • The treatment of visual impairment due to diabetic macular oedema (DME) • The treatment of proliferative diabetic retinopathy (PDR) • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • The treatment of visual impairment due to choroidal neovascularisation (CNV)
How to take
CACanada· Health Canada
5 products
Uses
LUCENTIS® (ranibizumab injection) is indicated in adults for: the treatment of neovascular (wet) age related macular degeneration (AMD). the treatment of visual impairment due to diabetic macular edema (DME). the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM). the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy.
LUCENTIS is indicated in preterm infants for: the treatment of retinopathy of prematurity (ROP) with zone I [stage 1 with plus disease (1+), stage 2 with plus disease (2+), or stage 3 with or without plus disease (3 or 3+)], or zone II [stage 3 with plus disease (3+)] or aggressive posterior ROP (AP-ROP) disease.
Drug interactions
Known interactions involving Ranibizumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011102 · revised March 13, 2026
- [2]European Medicines Agency · EMEA/H/C/006502 · revised May 29, 2026
- [3]Health Canada (DPD) · 02296810 · revised July 29, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.